Brief: Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV

Precision BioSciences

14/02/2024 12:20

Feb 14 (Reuters) - Precision BioSciences Inc  DTIL.O :
    * PRECISION BIOSCIENCES RECEIVES PRE-IND FEEDBACK FROM US
FDA FOR
PBGENE-HBV AS IT ADVANCES TOWARDS CLINICAL READINESS
    * PRECISION BIOSCIENCES INC - REGULATORY FEEDBACK AND
ALIGNMENT
FROM BOTH U.S. AND EX-U.S. REGULATORS SUPPORTS CLINICAL
DEVELOPMENT PATH FOR PBGENE-HBV
    * PRECISION BIOSCIENCES - IND/CTA ENABLING STUDIES WITH
FINAL
CLINICAL CANDIDATE UNDERWAY FOR PBGENE-HBV PROGRAM; EXPECT TO
FILE IND AND/OR CTA IN 2024

Source text for Eikon:  ID:nBw6b8pyba 
Further company coverage:  DTIL.O 

 ((Reuters.Briefs@thomsonreuters.com;))